Chromadex, a supplier of the NAD+ boosting nicotinamide riboside (NR) ingredient called Tru Niagen, has launched a new test kit to measure blood NAD+ levels for the healthcare practitioner (HCP) channel.

The new kit provides practitioners with a reliable method for measuring patient blood NAD+ levels, and is intended by Chromadex to be used in conjunction with its products to ensure effective patient protocols.

The suite of Tru Niagen supplements, all of which contain NR, includes Niagen+, a pharmaceutical-grade nicotinamide riboside chloride, which will soon be available as Niagen IV and injections at clinics on a prescription basis.

“Our healthcare practitioners have requested a tool to measure blood NAD+ levels, and we believe this is the best product now available on the market,” said Rob Fried, CEO of Chromadex and founder of Tru Niagen.

The new NAD+ test kit features novel dried blood spot (DBS) assay technology, which ensures the stability of NAD+ samples during transport for precise and accurate results. Other test kits use a less reliable DBS card, which requires adding a fixer solution to stabilize NAD+, which often degrades during the DBS drying process, Chromadex reports.

The new test kit features the company’s novel test card technology, and tracking from baseline in order to evaluate changes over time with NAD+ boosting treatment.

The company’s results are conducted at Clinical Laboratory Improvement Amendments (CLIA)- and College of American Pathologists (CAP)-accredited clinical genomics and biochemical testing laboratory with expertise in mass spectrometry-based assays. All blood samples are tested using high-resolution liquid chromatography/tandem mass spectrometry (LC-MS/MS).

How It Works

HCPs will provide patients with an at-home Niagen+ NAD+ test kit, which patients will register on the 1health platform. Once registered, patients will follow instructions on the kit to produce a sample and send it to the lab with a prepaid envelope. Results will be available to both patients and doctors in about two weeks through 1health.

“We are proud to partner with ChromaDex to bring this innovative testing solution to healthcare practitioners. Our robust software seamlessly integrates with both the warehouse and the lab, ensuring efficient fulfillment of kits and accurate delivery of results. This collaboration provides invaluable insights for practitioners aiming to optimize their patients’ NAD+ levels, enabling personalized and effective NAD+ boosting protocols, such as Tru Niagen oral supplementation and soon Niagen IV and injection, to maximize therapeutic outcomes,” said Mehdi Maghsoodnia, CEO of 1health.